CASI Pharmaceuticals (CASI, Financial) experienced a significant stock movement with a 5.22% drop in share price, currently trading at $2.54. The trading volume reached 2,093 shares, with a turnover rate of 0.01% and a fluctuation of 4.85%. Recent financial reports indicate a revenue of $7.79 million, a net loss of $8.40 million, and an earnings per share of -$0.55. The gross profit stood at $4.05 million, with a price-to-earnings ratio of -1.14. Notably, all participating analysts recommend a buy rating for CASI.
In the broader biotechnology sector, which saw an overall decline of 0.12%, stocks like Clearmind Medicine Inc. and 180 Life Sciences Corp. showed significant gains. CASI Pharmaceuticals focuses on commercializing innovative therapies, mainly generating revenue from its EVOMELA product, used in treatments related to leukemia and lymphoma. The company operates in the U.S., Canada, China, and other regions worldwide.
